Zacks Investment Research upgraded shares of Uniqure (NASDAQ:QURE) from a hold rating to a buy rating in a research report sent to investors on Wednesday. Zacks Investment Research currently has $33.00 price target on the biotechnology company’s stock.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other research analysts have also recently issued reports on the stock. HC Wainwright raised their price target on shares of Uniqure from $42.00 to $48.00 and gave the stock a buy rating in a report on Monday, September 24th. Cantor Fitzgerald set a $58.00 price target on shares of Uniqure and gave the stock a buy rating in a report on Thursday, August 23rd. BidaskClub raised shares of Uniqure from a buy rating to a strong-buy rating in a report on Thursday, August 9th. Janney Montgomery Scott reaffirmed a buy rating on shares of Uniqure in a report on Wednesday, August 8th. Finally, Cowen reaffirmed a buy rating on shares of Uniqure in a report on Monday, August 13th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Uniqure currently has an average rating of Buy and an average target price of $44.33.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.04. The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.37 million. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. As a group, sell-side analysts forecast that Uniqure will post -2.44 earnings per share for the current year.
Several institutional investors have recently modified their holdings of QURE. OppenheimerFunds Inc. purchased a new position in shares of Uniqure during the second quarter worth $63,553,000. Redmile Group LLC purchased a new position in shares of Uniqure during the second quarter worth $61,402,000. Millennium Management LLC raised its holdings in shares of Uniqure by 242.8% during the first quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after purchasing an additional 538,031 shares during the last quarter. FMR LLC raised its holdings in shares of Uniqure by 16.6% during the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock worth $139,659,000 after purchasing an additional 526,283 shares during the last quarter. Finally, Eventide Asset Management LLC purchased a new position in shares of Uniqure during the first quarter worth $7,873,000. 59.32% of the stock is owned by hedge funds and other institutional investors.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Further Reading: How are the companies in the S&P 500 selected?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.